Johnson & Johnson (JNJ) Shares Sold by Cibc Bank USA
Cibc Bank USA lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,673 shares of the company’s stock after selling 2,801 shares during the period. Cibc Bank USA’s holdings in Johnson & Johnson were worth $2,630,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Gardner Russo & Gardner LLC grew its stake in Johnson & Johnson by 30.4% during the 1st quarter. Gardner Russo & Gardner LLC now owns 1,715 shares of the company’s stock worth $220,000 after buying an additional 400 shares during the last quarter. Spectrum Management Group Inc. grew its stake in Johnson & Johnson by 2.8% during the 1st quarter. Spectrum Management Group Inc. now owns 14,841 shares of the company’s stock worth $1,902,000 after buying an additional 410 shares during the last quarter. Mountain Pacific Investment Advisers Inc. ID grew its stake in Johnson & Johnson by 1.4% during the 1st quarter. Mountain Pacific Investment Advisers Inc. ID now owns 29,762 shares of the company’s stock worth $3,814,000 after buying an additional 417 shares during the last quarter. Hodges Capital Management Inc. grew its stake in Johnson & Johnson by 0.8% during the 1st quarter. Hodges Capital Management Inc. now owns 54,284 shares of the company’s stock worth $6,956,000 after buying an additional 417 shares during the last quarter. Finally, Southeast Asset Advisors Inc. grew its stake in Johnson & Johnson by 0.7% during the 1st quarter. Southeast Asset Advisors Inc. now owns 60,947 shares of the company’s stock worth $7,810,000 after buying an additional 418 shares during the last quarter. 66.80% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson stock opened at $139.49 on Monday. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32. The company has a market capitalization of $373.89 billion, a P/E ratio of 19.11, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were paid a $0.90 dividend. The ex-dividend date was Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.58%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In related news, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is owned by insiders.
Several research analysts have weighed in on the company. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research note on Friday. ValuEngine downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. Jefferies Financial Group set a $145.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, June 12th. Finally, Sanford C. Bernstein assumed coverage on Johnson & Johnson in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 target price on the stock. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $142.87.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Penny Stocks
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.